Key statistics
As of last trade ProMIS Neurosciences Inc (PMN:NAQ) traded at 1.01, 6.15% above its 52-week low of 0.95, set on Dec 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.10 |
---|---|
High | 1.10 |
Low | 1.00 |
Bid | 1.00 |
Offer | 1.01 |
Previous close | 1.03 |
Average volume | 67.37k |
---|---|
Shares outstanding | 20.13m |
Free float | 12.26m |
P/E (TTM) | -- |
Market cap | 20.73m USD |
EPS (TTM) | -0.6924 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 16:59 BST.
More ▼
Announcements
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
- ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
- ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
- ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
More ▼